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Abstract
Introduction: In high‐income countries the majority of pregnancies have a good out‐
come, and many adverse obstetric outcomes rarely occur. This makes demonstrating 
clinically relevant and statistically significant effects of new interventions a chal‐
lenge. The objective of the study was to report incidences of important obstetric 
outcomes and to calculate sample sizes for tentative studies.
Material and methods: The study was a registry‐based study. Data were retrieved 
from the Danish Medical Birth Registry and included all deliveries in Denmark from 
2008 to 2015. The total population included 465 919 deliveries. The study population 
comprised intended vaginal deliveries with a single fetus in cephalic presentation at term 
(n = 381 567). Incidences were reported for 20 outcomes considering the relevance for 
the patients and the severity of the outcomes. We calculated the sample sizes required 
in tentative obstetric studies to detect risk reductions of 25 and 50%, for tests at the 5% 
level, using a power of 80 and 90%. For the randomized controlled trials we calculated 
the sample size required for comparing two proportions with equal‐sized groups. For 
the cohort study we calculated the sample size also required for two proportions 
but with unequal sized groups. Outcome measures for sample size calculation were 
neonatal mortality, Apgar score <7 at 5 minutes and emergency cesarean section.
Results: The incidence of neonatal mortality, Apgar score <7 at 5 minutes and emergency 
cesarean section was 0.05, 0.58 and 10.5%, respectively. Using neonatal mortality as 
the outcome in a tentative randomized controlled trial with an expected risk reduction 
of 50% and power of 80%, our calculation showed a sample size of 195 036 deliveries. 
Using Apgar score <7 at 5 minutes or emergency cesarean section as the outcome, 16 254 
and 818 deliveries, respectively, were required. In tentative cohort studies, the required 
sample sizes were larger due to the unequal proportion of exposed/non‐exposed women.
Conclusions: Most adverse obstetric outcomes occur rarely; thus, very large sample 
sizes are required to achieve adequate statistical power in randomized controlled 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
In high‐income countries the majority of pregnancies have a good 
outcome, and many adverse obstetric outcomes rarely occur. This 
makes demonstrating clinically relevant and statistically significant 
effects of new interventions a challenge.
Randomized controlled trials (RCTs) are considered the gold 
standard for establishing causal inference in healthcare interven‐
tions, and are therefore frequently applied as study designs.1,2 If 
RCTs have adequate statistical power, the expectation is that signifi‐
cant differences between groups will be a result of the intervention.1
To ensure the quality of scientific work, calculating and reporting 
a study's sample size is fundamental.2 However, sample size calcu‐
lations are sparsely reported in scientific papers, and many trials do 
not achieve the target sample size stated before starting the trial.3 
When a study is underpowered, there is a risk of not finding the true 
difference between the groups, affecting the quality of the study.4 
Two obstetric papers from 1997‐2000 on the introduction of contin‐
uous electronic fetal monitoring in obstetric care and on the poten‐
tial bias when comparing small and large maternity institutions when 
studying stillbirth rates, respectively, discuss the implications of 
study design, rare outcome measures and large sample sizes.5,6 The 
two studies concluded that, for rare outcomes, very large sample 
sizes were needed to detect statistically significant differences be‐
tween study groups. Even though these two studies emphasize the 
implications of sample size calculation in obstetric outcomes, many 
researchers still include rare outcomes in their study design without 
having sufficient power to do so.
Our study had three objectives: first, to report incidences of 16 
obstetric outcomes; secondly, to calculate sample sizes for tentative 
studies using three selected outcomes: neonatal mortality, Apgar 
score <7 at 5 minutes and emergency cesarean section (ECS); and 
thirdly, to discuss the implications for study design in obstetrics 
when choosing outcome measures.
2  | MATERIAL AND METHODS
2.1 | Population and study design
The study was a registry‐based study. Data were retrieved from the 
Danish Medical Birth Registry and included all deliveries in Denmark 
from 2008 to 2015. The Danish Medical Birth Registry contains in‐
formation on all deliveries in Denmark, thus providing data on the 
mother, the child, the pregnancy and the delivery.
The annual number of deliveries in Denmark is approximately 
60 000, with 96‐98% of deliveries in public hospitals and 2‐3% at 
home, mostly attended by midwives from public maternity depart‐
ments.7 Currently there are 23 public maternity departments in 
Denmark, all with access to specialists in obstetrics and anesthesi‐
ology. Midwives attend all deliveries and an obstetrician is only in‐
volved in the event of complications.
In this study we operated with two populations: the total popu‐
lation and the study population. We used the former, which included 
all deliveries in Denmark in the study period, to report incidences of 
important obstetric outcomes.
For calculating sample sizes for tentative studies, we used a 
study population that included all intended vaginal deliveries with a 
term (gestational age ≥37 weeks) singleton in cephalic presentation. 
Stillbirths and homebirths were excluded. Incidences of the obstet‐
ric outcomes were also reported for the study population.
2.2 | Outcome measures
It is the scientific question raised that defines whether an obstetric 
event is an intervention, an outcome or even a population, not the 
event itself. In our study we have defined 16 relevant and used 
obstetric outcomes in the literature and are aware that these 
outcomes in other studies could be defined as interventions or 
constitute a study population.
We chose 16 obstetric outcomes for reporting incidences of the 
total population: preeclampsia, hemolysis, elevated liver enzymes, 
and low platelets (HELLP) syndrome, eclampsia, induction of labor, 
oxytocin augmentation, umbilical cord prolapse, shoulder dystocia, 
vacuum extraction, ECS, postpartum hemorrhage ≥1000 mL, man‐
ual exploration of the uterus, stillbirth, Apgar score <7 at 5 minutes, 
preterm delivery <37 weeks of gestation, low birthweight <2500 g 
and neonatal mortality. We chose these outcomes considering the 
trials. Multicenter studies, international collaborations or alternative study designs to 
randomized controlled trials could be considered.
K E Y W O R D S
emergency cesarean section, incidence, methods, obstetric outcome, obstetrics, pregnancy 
outcome, research design, sample size
Key message
The majority of obstetric outcomes occur with a very low 
incidence. Our sample size calculations showed that when 
using rare obstetric outcomes large sample sizes were re‐
quired. Multicenter studies, international collaborations or 
alternative study designs to randomized controlled trials 
could be considered.
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relevance for the patients and the severity of the outcomes. For the 
study population we report incidences of 14 obstetric outcomes.
For sample size calculation in tentative studies, we chose three 
outcomes from the core outcome set for key stakeholders in mater‐
nity care: neonatal mortality, Apgar score <7 at 5 minutes and ECS.8 
The chosen outcomes reflect different incidences: one extremely 
rare, one rare and one more common.
Neonatal mortality is defined as death before the age of 28 com‐
pleted days after live birth.9 Apgar score is used to assess the condi‐
tion of the newborn at 1 and 5 minutes after birth and it is a validated 
predictor of neonatal survival.10 The Apgar score at 5 minutes is the 
best predictor of neonatal survival.10 Cesarean section is linked to a 
wide range of complications, such as uterine rupture and abnormal 
invasive placenta, which leads to higher risk of maternal and neona‐
tal morbidity and mortality.11
2.3 | Statistical analyses
The data have been used as part of another study.12 Before analysis, 
the dataset was checked for logical errors. We recoded missing data 
for maternal weight and height with unrealistic values and checked 
whether there was consistency between the diagnosis of the deliv‐
ery and the surgical intervention or procedure coded.
The selected outcomes are reported as incidences, both for 
the total population and for the study population. The incidences 
of neonatal mortality, Apgar score <7 at 5 minutes and ECS in the 
study population formed the basis for the tentative sample size cal‐
culations. We calculated the sample sizes for the comparison of two 
proportions, which necessitates a proportion of the outcome, and 
the researcher to consider the intervention effect and the desired 
maximum risk of statistical errors. The statistical tool is provided in 
Supporting Information Appendix S1.
We calculated the sample size necessary for tentative RCTs and 
cohort studies to be able to detect risk reductions of 25 and 50% at 
the 5% level with a power of 80 and 90%, respectively. For the RCTs 
we calculated the sample size required for comparing two propor‐
tions with equal‐sized groups (i.e. 1:1 ratio), whereas for the cohort 
study we calculated the sample size also required for two propor‐
tions but with unequal sized groups. We calculated sample sizes for 
proportion of exposed women of 5, 10 and 25%.13
Incidences were computed using IBM SPSS® version 24 (IBM 
Corp., Armonk, NY, USA) and sample size calculations were made 
using SAS® software package version 9.4 (SAS Institute, Cary, NC, 
USA). As missing data were rare, imputation was not applied.
2.4 | Ethical approval
Approval was obtained from the Danish Data Protection Agency 
(file no.: 2012‐58‐0004). As this was a registry‐based study, ethical 
approval was not required according to the Danish Research Ethics 
Committee Law.14
TA B L E  1   Sociodemographic characteristics of the total 
population and the study population in Denmark from 2008 to 
2015
Characteristics
Total populationa
n (%)
465 919 (100)
Study populationb
n (%)
381 567 (100)
Singleton deliveries 456 014 (97.9) 381 567 (100)
Twin deliveries 9794 (2.1) —
Triplet/quadruplet 
deliveries
111 (0.0) —
Breech deliveries 19 244 (4.1) —
Singleton vaginal 
breech deliveries
1987 (0.5) —
Planned cesarean 
section
43 407 (9.3) —
Gestational age
<37 weeks 30 544 (6.6) —
37+0 to 39+6  
weeks
206 986 (44.4) 159 973 (41.9)
≥40 weeks 228 193 (49.0) 221 594 (58.1)
Missing data 196 (0.0) —
Maternal age (years)
<25 57 907 (12.4) 49 985 (13.1)
25‐34 310 442 (66.6) 257 365 (67.4)
35‐39 81 335 (17.5) 62 532 (16.4)
≥40 16 235 (3.5) 11 685 (3.1)
Parity
Nulliparous 212 445 (45.6) 177 674 (46.6)
Multiparous 248 976 (53.4) 203 893 (52.5)
Missing data 4498 (1.0) 3605 (0.9)
Smoking during pregnancy
No 402 816 (86.5) 330 631 (86.7)
Smoking cessation 
during pregnancy
13 676 (2.9) 11 588 (3.0)
1‐20 cigarettes per 
day
41 061 (8.8) 33 215 (8.7)
>20 cigarettes per 
day
1417 (0.3) 1095 (0.3)
Missing data 6949 (1.5) 5038 (1.3)
Body mass index (kg/m2)
<18.5 18 321 (3.9) 15 054 (3.9)
18.5‐24.9 276 318 (59.3) 229 585 (60.2)
25‐29.9 95 519 (20.5) 77 202 (20.2)
30‐34.9 37 128 (8.0) 29 342 (7.7)
≥35 20 302 (4.4) 15 618 (4.1)
Missing data 18 331 (3.9) 14 766 (3.9)
aThe total population included all deliveries with gestational age 20+0 
to 45+0. 
bThe study population included all term singleton (≥37 weeks of gesta‐
tional age) with intended vaginal cephalic delivery. 
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3  | RESULTS
From 2008 to 2015, there were 465 919 deliveries in Denmark. The 
study population, including intended vaginal deliveries with term 
singletons in cephalic presentation, consisted of 381 567 deliveries. 
There were missing data for Apgar score <7 at 5 minutes in 1260 de‐
liveries (0.3%). There was no missing data for the variables neonatal 
mortality or ECS.
Table 1 shows the sociodemographic characteristics of the 
total population and the study population. In general, Danish 
women were most likely to deliver at term, to be 25‐34 years of 
age, to be non‐smokers, and to have a normal body mass index (i.e. 
18.5‐24.9 kg/m2).
Table 2 reports incidences of the 16 obstetric outcomes. Most 
outcomes occurred at a low incidence. The only outcomes with an 
incidence >10% were induction, oxytocin augmentation of labor and 
ECS. In the total population, the incidence of neonatal mortality, 
Apgar score <7 at 5 minutes and ECS was 0.4, 0.9 and 12.2%, respec‐
tively. In the study population, the incidence of neonatal mortality, 
Apgar score <7 at 5 minutes and ECS was 0.05% (95% confidence 
interval (CI) 0.04‐0.06), 0.58% (95% CI 0.55‐0.60) and 10.5% (95% 
CI; 10.4‐10.6), respectively.
Table S1 reports incidences of the obstetric outcomes stratified 
by year.
Figure 1 and Table 3 report the sample sizes calculated for 
tentative RCTs and cohort studies. As shown, the incidence of the 
outcome measure affected the sample size. When using neonatal 
mortality with an incidence of 0.05% as the outcome in a tentative 
RCT with an expected risk reduction of 50% and power of 80%, our 
sample size calculation showed required sample size of 195 036 
deliveries. Using Apgar score <7 at 5 minutes, with an incidence of 
0.58%, as the outcome in a tentative RCT, with the same risk reduc‐
tion and same power, 16 254 deliveries were required. For ECS with 
an incidence of 10.5%, 818 deliveries were required for a tentative 
RCT. Figure 1 and Table 3 also report the sample sizes required for 
studies with a power of 90% and for studies with a risk reduction 
of 25%.
Our results illustrate that an expected lower risk reduction in‐
creased the sample sizes. Using neonatal mortality as the outcome 
in a tentative RCT with 80% power and changing the risk reduction 
from 50% to 25% resulted in a fourfold increase in the required sam‐
ple size to 916 518 deliveries. Using Apgar score <7 at 5 minutes or 
ECS as outcomes, the same fourfold increase in the required sample 
size was seen when the expected risk reduction changed from 50% 
to 25% (Figure 1, Table 3).
Our results furthermore illustrate that changing the power from 
90% to 80% had a small impact on the required sample sizes. Using 
Apgar score <7 at 5 minutes as the outcome in a tentative RCT with 
50% risk reduction and 80% power instead of 90%, the required 
sample size decreased from 21 758 to 16 254 deliveries. Using ECS 
as the outcome in an RCT with 50% risk reduction and 80% power 
instead of 90%, the required sample size decreased from 1092 to 
818 deliveries (Figure 1, Table 3).
The study design furthermore affected the required sample 
sizes. When changing the proportion of exposed women from 50% 
to a smaller proportion, larger sample sizes were required. If Apgar 
score <7 at 5 minutes was used as the outcome in a tentative co‐
hort study with 25% exposed instead of an RCT (50% exposed) 
with a power of 80% and risk reduction of 50%, the required 
sample size increased from 16 254 deliveries to 20 112 deliveries 
(Table 3). The same tendency was seen when the proportion of ex‐
posed women was even smaller. If the proportion of exposed was 
10%, the required sample size was 39 680, and if the proportion of 
TA B L E  2   Incidences of obstetric outcomes in Denmark from 
2008 to 2015
Outcomea
Total populationb
n (%)
465 919 (100)
Study populationc
n (%)
381 567 (100)
Pregnancy outcomes
Preeclampsia 13 874 (3.0) 9836 (2.6)
HELLP 1177 (0.3) 472 (0.1)
Eclampsia 249 (0.05) 147 (0.04)
Induction of labor 102 499 (22.0) 93 174 (24.4)
Delivery outcomes
Oxytocin 
augmentation
100 791 (21.6) 92 975 (24.4)
Umbilical cord 
prolapse
514 (0.1) 275 (0.1)
Shoulder dystocia 4449 (1.0) 4344 (1.1)
Vacuum extraction 32 816 (7.0) 30 943 (8.1)
Emergency cesarean 
section
56 619 (12.2) 40 416 (10.6)
Postpartum hemor‐
rhage ≥1000 mL
10 627 (6.4) 8393 (6.2)
Manual exploration 
of the uterus
6634 (1.4) 4858 (1.3)
Neonatal outcomes
Stillbirth 1721 (0.4) —
Apgar score <7 at 
5 minutes
4034 (0.9) 2201 (0.58)
Preterm deliv‐
ery <37 weeks’ 
gestation
30 544 (6.6) —
Low birthweight 
<2500 g
21 648 (4.6) 4949 (1.3)
Neonatal mortality 1310 (0.3) 184 (0.05)
Abbreviation: HELLP, hemolysis, elevated liver enzymes, and low 
platelets.
aOne delivery can be represented more than once. 
bThe total population included all deliveries in Denmark from 2008 to 
2015 with gestational age 20+0 to 45+0 weeks. In the event of multi‐
ple fetuses in one pregnancy, an outcome among one or more of the 
children counts. 
cThe study population included all term (≥37 weeks’ gestational age), 
singleton, intended vaginal cephalic delivery in Denmark from 2008 to 
2015. 
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exposed was 5%, the sample size was further increased to 73 680 
deliveries (Table 3).
Table S2 reports the required sample sizes for all 14 outcomes 
from the study population.
4  | DISCUSSION
We found that the majority of obstetric outcomes occurred at a very 
low incidence.
F I G U R E  1   The total sample size 
required for tentative randomized 
controlled trials (1:1) and cohort studies 
(1:3, 1:9, 1:19) with neonatal mortality, 
Apgar score <7 at 5 minutes (<7/5) and 
emergency cesarean section as the 
outcome. Changes of a 25 and 50% 
reduction in outcomes are plotted against 
incidences, using an 80 and 90% power 
and a 5% significance level [Color figure 
can be viewed at wileyonlinelibrary.com]
TA B L E  3   Sample sizes for tentative randomized controlled trials and cohort studiesa
Outcome (incidence)
Power
Risk reduction
50% 25%
Proportion of exposed Proportion of exposed
5% 10% 25% 50% 5% 10% 25% 50%
Neonatal mortality (0.05%)
80% 884 820 476 510 241 584 195 036 4 576 400 2 431 690 1 190 132 916 518
90% 1 259 520 673 250 334 172 261 096 6 280 940 3 327 940 1 615 172 1 226 960
Apgar score <7 at 5 minutes (0.58%)
80% 73 680 39 680 20 112 16 254 377 260 200 460 98 112 75 786
90% 104 840 56 040 27 816 21 758 517 760 274 340 133 148 101 454
Emergency cesarean section (10.6%)
80% 3740 2010 1016 818 18 820 10 000 4884 3764
90% 5300 2830 1400 1092 25 760 13 650 6620 5038
aTotal sample sizes required for tentative classical randomized controlled trials with an allocation of 1:1 ratio (i.e. 50% exposed) and cohort studies 
with a proportion of exposed of 5, 10 and 25%. 
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Our sample size calculations showed that the choice of study de‐
sign, the outcome incidence and the change from 50% to 25% in the 
risk reduction all contributed to the required sample size of the ten‐
tative studies. Changing the power from 90% to 80% did not have 
large impact on the required sample size.
A strength of our study is that the reported incidences are based 
on a large data source of 456 014 deliveries and the sample size cal‐
culations on a data source of 381 567 deliveries. The deliveries rep‐
resent the period from 2008 to 2015, making the data fairly current.
Registry‐based research always involves the uncertainty asso‐
ciated with inaccurate reporting. Several studies show, however, 
that data from the Danish Medical Birth Register are valid in terms 
of diagnosis on most well‐defined outcomes, such as preeclampsia, 
birthweight, oxytocin augmentation of labor, vacuum extraction and 
cesarean section.15,16
The study demonstrated that low incidence of the outcome 
affected the sample size. In Danish settings, if an RCT with 90% 
power was required to show a significant reduction of 25% of Apgar 
score <7 at 5 minutes, the study would take more than 2 years and 
require the inclusion of all deliveries. However, it might not be pos‐
sible to include all eligible patients and some do not want to partic‐
ipate in the study. Thus, the time it takes to recruit patients will be 
longer than anticipated. This entails the researcher in the planning 
phase of an RCT to be realistic about recruitment and retention of 
participants in the study. This could be done through a feasibility 
study.
Our sample size calculations showed that a major contributor 
to the required sample size was the change from 50% to 25% in 
the risk reduction. Applying a risk reduction of 50% instead of 
25% to the sample size calculation in a tentative RCT with a rare 
outcome such as Apgar score <7 at 5 minutes would still require 
a large‐scale multicenter study. Multicenter studies have the ad‐
vantage of including more participants in shorter time. However, 
multicenter studies are considerably more complex to run than sin‐
gle‐site studies. Furthermore, the sample size calculations depend 
upon the assumption that the differences between the compared 
interventions in the centers are unbiased estimates of the same 
quantity. Based on previous studies, a reduction in risk of 50% or 
25% in Apgar score <7 at 5 minutes is probably unrealistic.17,18 A 
realistic and still clinically important reduction in Apgar score <7 
at 5 minutes might be 10%, which would require an even larger 
sample size.
With a more common outcome such as ECS, conducting RCTs 
is more feasible because of the requirement of smaller sample sizes 
to achieve the adequate power. This might explain why ECS is often 
seen as an outcome in obstetric studies.17,19‐21 ECS may be a rel‐
evant outcome, but it is also easier to obtain power to show sta‐
tistically significant results compared with a more rare outcome. 
Furthermore, in many studies an effect on the more common out‐
comes is often found and the interpretation is that a given interven‐
tion has only affected these common outcomes. The intervention, 
however, could potentially also have affected the rare outcomes, but 
the study might be underpowered to show this effect.
Meta‐analyses of RCTs are a way of increasing the power of the 
estimated intervention effect. However, meta‐analyses are, like sin‐
gle‐site studies, prone to risk of systematic and random error.22,23
Sometimes used in studies with rare outcomes,24‐26 composite 
outcomes combine several variables, which are considered to be 
equivalent, into one outcome to increase the total incidence of these 
outcomes. Composite outcomes enable the study to be performed 
with a smaller sample and/or in less time. However, composite out‐
comes often provide an unclear reflection of the effect because 
the outcomes are not necessarily equivalent in terms of severity or 
measurements, and it is possible that the exposure increases the risk 
of one complication and decreases the risk of another. In the latter 
situation, the possible effect of the exposure may be camouflaged.27
RCTs are considered the gold standard for establishing causality 
between exposure and outcome in healthcare interventions.1,2 RCTs 
are usually expensive and time‐consuming, and not all research ques‐
tions can be answered by interventional studies due to ethical consid‐
erations. A possible alternative study design to RCTs is observational 
studies, such as cohort or case–control studies. These designs facili‐
tates studies using rare outcomes as they allow for inclusion of large 
populations due to no intervention and no treatment, just as the expo‐
sure does not have to be administered to the participants.28 Thus, even 
though our sample size calculations revealed larger sample sizes for 
cohort studies of unequal groups, also when studying rare outcomes 
such as Apgar score <7 at 5 minutes, obtaining the required sample size 
in a cohort study would be easier than in an RCT. This design would 
even allow studying rare outcomes of low exposure and also even with 
a relatively low reduction in risk. There is a limitation when studying 
extremely rare outcomes because the required sample sizes will be 
extremely large, making it impossible to recruit participants within a 
reasonable time frame. Cohort studies, however, have the limitations 
that they are prone to bias, the data may be inaccurate and misclassi‐
fied, and deducing causal conclusions is not possible, weakening the 
study's internal validity. The International Network of Obstetric Survey 
Systems (INOSS), a multi‐country collaboration, facilitates studies of 
rare and severe outcomes in pregnancy and childbirth through inter‐
national cooperation.29 International collaborative work on registry‐
based data might be a good approach to obtain sufficient sample size 
when studying rare outcomes. Sometimes RCTs are not the most fea‐
sible study design, and many historical cases exist in which treatments 
with a convincing change are based on observational studies.30
The attention given to relevant outcome measures, as in the 
CROWN initiative31 is very important to obtain high quality evi‐
dence, but it is also essential to consider whether an RCT with rare 
outcomes is actually feasible, or if an alternative study design must 
be chosen. To our knowledge, the medical literature on sample size 
calculation and power regarding obstetric outcomes and choice of 
study design is sparse. Our results support the findings from two 
other studies investigating this issue. Mongelli et al demonstrated 
that when introducing electronic fetal monitoring, it was much eas‐
ier to detect an increase in the incidences of cesarean section than 
a reduction in morbidity because of the different sample sizes and 
time needed to detect a significant change in the two outcomes.5 
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Moster et al demonstrated that large sample sizes were needed 
when comparisons of safety between different sizes of delivery 
units were made for low‐risk pregnancies, including stillbirth as the 
outcome measure.6 Our findings furthermore provide insights into 
sample sizes in relation to study design in both rare and more com‐
mon obstetric outcomes.
5  | CONCLUSION
Based on Danish national data from an 8‐year period, we found that 
several obstetric outcomes occur rarely. Consequently, very large 
sample sizes are required to achieve adequate statistical power in 
tentative RCTs. This necessity entails a risk of studies being under‐
powered or only showing an effect on common outcomes when an 
effect on rare outcomes might also exist.
Focusing on international multicenter collaboration and prioritiz‐
ing a feasible study design can provide high quality evidence when 
investigating rare outcomes.
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